People with rare mutations in the myostatin gene have lower body fat percentage and less total fat tissue, as measured by MRI and bioimpedance in a study of more than 77,000 people.
See the scientific wording
Carriers of rare, function-disrupting myostatin gene variants exhibit significantly lower body fat percentage and reduced total adipose tissue volume, as measured by whole-body MRI and bioimpedance in a cohort of over 77,000 individuals.
Correlational — new studies may shift this
ObservationalOne moderate-quality study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Cohort StudyHuman2026
People born with a rare gene change that limits myostatin end up with more muscle and less fat, and this study proved it by scanning over 77,000 people’s bodies. So yes, less myostatin = more muscle and less fat, together.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
When the myostatin protein is disrupted, muscles grow larger because their growth signals are no longer blocked. Larger muscles require more energy, so the body burns more fat to fuel them, leading to less fat storage overall.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
People with rare mutations in the myostatin gene have lower body fat percentage and less total fat tissue, as measured by MRI and bioimpedance in a study of more than 77,000 people.
Mechanism
1 studyWhen myostatin doesn't work, muscles grow bigger because their growth signals are no longer blocked. Bigger muscles burn more energy, so the body uses fat for fuel instead of storing it, leading to less body fat.
When the myostatin protein is disrupted, muscles grow larger because their growth signals are no longer blocked. Larger muscles require more energy, so the body burns more fat to fuel them, leading to less fat storage overall.
Function-disrupting variants in the myostatin gene alter the structure of the myostatin precursor protein, preventing its proper maturation and secretion.
Reduced levels of bioactive myostatin ligand decrease binding to ActRIIA/B and ALK4/5 receptors on skeletal muscle cells.
De-repression of the SMAD2/3 signaling pathway enhances satellite cell activation, myoblast proliferation, and protein synthesis in skeletal muscle.
Skeletal muscle mass increases significantly across multiple muscle groups due to hypertrophy.
Increased muscle mass elevates basal metabolic rate and systemic energy expenditure, shifting energy partitioning away from adipose tissue storage.
Adipose tissue accumulation is reduced due to decreased lipid storage and reduced fat infiltration within muscle.
Evidence from Studies
Supporting (1)
Community contributions welcome
People born with a rare gene change that limits myostatin end up with more muscle and less fat, and this study proved it by scanning over 77,000 people’s bodies. So yes, less myostatin = more muscle and less fat, together.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Myostatin Gene Variants and Body Fat Metrics in Large Cohorts
Population: Adults with confirmed rare myostatin loss-of-function variants and matched controls; Intervention: None (observational); Comparator: Non-carriers; Outcome: Body fat percentage and adipose tissue volume measured by MRI and bioimpedance; Duration: Single time point.
Randomized Trial of Myostatin Inhibition vs Placebo on Adipose Tissue Volume in Healthy Adults
Population: Healthy adults without myostatin mutations; Intervention: Myostatin-blocking agent (e.g., antibody or gene therapy); Comparator: Placebo; Outcome: Change in body fat percentage and adipose tissue volume via MRI and bioimpedance; Duration: 12 months.
Prospective Cohort Study of Myostatin Variant Carriers and Long-Term Body Composition Outcomes
Population: 77,000 individuals genotyped for myostatin variants; Intervention: None; Comparator: Non-carriers; Outcome: Annual measurements of body fat percentage and adipose tissue volume over 10 years; Duration: 10 years.
Cross-Sectional Analysis of Myostatin Variants and Body Fat in a Population-Based Biobank
Population: 77,000 individuals from a biobank with genotype and body composition data; Intervention: None; Comparator: Non-carriers; Outcome: Body fat percentage and adipose tissue volume at baseline; Duration: Single time point.
In Vitro Study of Myostatin Knockdown in Human Adipocyte Precursor Cells and Lipid Accumulation
Population: Human adipose-derived stem cells; Intervention: Myostatin siRNA or CRISPR knockout; Comparator: Scrambled control; Outcome: Lipid droplet volume and adipogenic gene expression; Duration: 14 days.